


Fig. S2



**Figure S2.** CSPG4 expression in PBMC and CAR T cells after Decitabine treatment. **(a)** Contour plots showing CSPG4-staining of PBMC days after daily addition of PBS or Decitabine at 1  $\mu\text{M}$ . One representative donor out of three experiments is depicted. **(b)** Contour plots showing CSPG4-staining of CSPG4-specific CAR T cells generated via mRNA-electroporation six days after daily addition of PBS or Decitabine at 1  $\mu\text{M}$ . One representative out of three experiments is depicted. **(c)** Cytotoxicity of CSPG4-CAR-T cells and mock T cells upon a 48h co-culture with SKOV-3 cells either treated with PBS or Decitabine for six days was assessed at the indicated effector to target ratios via an XTT-based colorimetric assay. Mock T cells (Red lines) and CSPG4-CAR-T cells (Blue lines) were either maintained at 1  $\mu\text{M}$  Decitabine following electroporation until completion of the killing assay (dotted lines) or were maintained in regular T cell medium after electroporation and throughout the killing assay (solid lines). Data represent means  $\pm$  SEM of three donors, p values were calculated by Student's t test, ns indicates not significant.